Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Qian Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2403-8092. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 4

  1. Prognostic value of composite inflammatory prognostic model in pancreatic cancer. Co-author DOI 10.1016/j.mcp.2025.102056↗
  2. Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer. Co-author DOI 10.2147/cmar.s304719↗
  3. EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum marker in pancreatic cancer. Co-author DOI 10.3892/mmr.2020.11384↗
  4. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. First author DOI 10.7150/thno.26650↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lijuan Wei · 2 shared papers, 2020–2025 · strength 0.46
  2. Li Ren · 2 shared papers, 2020–2021 · strength 0.33
  3. Matthew H. G. Katz · 1 shared paper, 2018 · strength 0.08
  4. Yang Liu · 1 shared paper, 2018 · strength 0.08
  5. Ye Hu · 1 shared paper, 2018 · strength 0.08
  6. Haiyong Han · 1 shared paper, 2018 · strength 0.08
  7. Eugene Jon Koay · 1 shared paper, 2018 · strength 0.08
  8. Jia Fan · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.